EUVIMEDEUVIMED entdecken
Open Access

Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer

Arlene Chan iD, Jespal Gill, HuiJun Chih iD, Sarah Christine Elisabeth Wright iD, Natali Vasilevski iD, Pieter Johan Adam Eichhorn iD

JCO Precision Oncology · 2024

DOI: 10.1200/po.24.00274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Arlene Chan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Research Centre-WA and Curtin University, Perth, Australia. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Breast Neoplasms, Furans, Ketones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The presence of epithelial-mesenchymal transition (EMT) in breast cancer (BC) cells has been linked to worse prognosis and may influence response to systemic treatment. We explored the effect of EMT in tumor samples of patients with metastatic BC on disease-free interval and overall survival in those patients receiving eribulin or cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). MATERIALS AND METHODS Key inclusion criteria included available archived primary BC tissue and, where available, matched metastatic biopsy. Patients received eribulin and/or a CDK4/6i in the metastatic setting. Specimens were assessed for biomarkers by immunohistochemistry (CDH1, AE1/3, VIM, CDH2, ZEB1, pSMAD2, and SMAD4) and gene expression by droplet digital polymerase chain reaction ( CDH1 , CDH2 , SNAI1 & 2 , TWIST1 , VIM , PTEN , and ZEB1 & 2 ). RESULTS Between 2002 and 2020, 127 patients were included (95 early-stage disease at diagnosis with metastatic relapse, 32 de novo metastatic disease). In metastatic samples, presence of ZEB1 overexpression was associated with shorter time to recurrence (48.1 months shorter; P = .003), with pSMAD2 overexpression suggesting clinical significance of 52.0 months shorter; P = .01. High gene expression levels for SNAIL1, TWIST1 , and PTEN in the primary BC were associated with significantly longer survival in patients who received eribulin ( P < .05); high VIM was associated with a clinically relevant trend toward shorter survival after a CDK4/6i ( P = .013). CONCLUSION We demonstrate in our exploratory study that biomarkers involved in the process of EMT could have a prognostic impact in a cohort of patients with BC uniformly treated and with long-term follow-up. Genes known to be involved in EMT were associated with improved eribulin efficacy, while suggesting a poorer outcome with CDK4/6i.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionBreast NeoplasmsFuransKetonesHumansFemaleMiddle AgedAgedAdultProtein Kinase InhibitorsNeoplasm Recurrence, LocalNeoplasm MetastasisAged, 80 and overPolyether Polyketides

Substanzen

eribulinFuransKetonesProtein Kinase InhibitorsPolyether Polyketides

Autor:innen und Institutionen

  • Breast Cancer Research Centre-WA and Curtin University, Perth, Australia.
  • Curtin Medical School, Curtin University, Bentley, Australia.
  • Anatomical Pathology, Western Diagnostics, Jandakot and PathWest, Murdoch, Australia.
  • School of Population Health, Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia.
  • Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia.

ORCID-Profile: Arlene Chan, HuiJun Chih, Sarah Christine Elisabeth Wright, Natali Vasilevski, Pieter Johan Adam Eichhorn

Zitieren

APA

Chan, A., Gill, J., Chih, H., Wright, S. C. E., Vasilevski, N., & Eichhorn, P. J. A. (2024). Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.24.00274

Vancouver

Chan A, Gill J, Chih H, Wright SCE, Vasilevski N, Eichhorn PJA. Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.24.00274

BibTeX
@article{Chan2024,
  author = {Chan, Arlene and Gill, Jespal and Chih, HuiJun and Wright, Sarah Christine Elisabeth and Vasilevski, Natali and Eichhorn, Pieter Johan Adam},
  title = {Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.24.00274}
}
Kostenlos starten →